ARCA biopharma, Inc. Banner Image

ARCA biopharma, Inc.

  • Ticker ABIO
    Exchange NASDAQ More
  • Industry Biotechnology More
  • Sector Healthcare More
ARCA biopharma, Inc. Logo Image
  • 11-50 Employees
  • Based in Westminster, Colorado
ARCA was founded on the belief that a precision medicine approach to drug development, tailoring medical treatment to the individual genetic characteristics of patients, can enable more effective therapies, improve patient outcomes and reduce healthcare costs. ARCA’s lead development program is intended to be a direct implementation of those ideas. Gencaro™ (bucindolol hydrochloride) isMore being developed as a potential treatment for atrial fibrillation (AF). ARCA has identified genetic variations in cardiac receptors that they believe may predict individual patient response to Gencaro™, giving Gencaro™ the potential to be the first genetically-targeted prevention treatment for AF.
ARCA biopharma, Inc.

Most Recent Annual Report

ARCA biopharma, Inc.
MOST RECENT 2022 Annual Report and Form 10K

Older/Archived Annual Reports

ARCA biopharma, Inc. Logo Image

Rate This Report

Your vote helps our reports be more useful
Rating Saved!

Thank you for your feedback!